Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits

被引:18
|
作者
Yoo, Ae Ri [1 ]
Chung, Sung Kun [2 ]
机构
[1] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Ophthalmol, Seoul, South Korea
[2] Catholic Univ Korea, St Pauls Hosp, Dept Ophthalmol & Visual Sci, Coll Med, Seoul 137701, South Korea
关键词
corneal neovascularization; tocilizumab; bevacizumab; subconjunctival; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS; INHIBITION; AVASTIN; ANTIBODY; DISEASES; UVEITIS; IL-6; VEGF;
D O I
10.1097/ICO.0000000000000220
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to compare the antiangiogenic effects of subconjunctival application of bevacizumab and tocilizumab on the regression of corneal neovascularization (NV) in rabbits. Methods: Corneal neovascularization was induced in 48 eyes of 24 rabbits. Seven days after suture placement, the rabbits were divided into 4 groups of 6 rabbits each and treated subconjunctivally with 0.1 mL balanced salt solution (group 1), 0.1 mL tocilizumab (0.25 mg per 0.1 mL and 2.5 mg per 0.1 mL, groups 2 and 3), or 0.1 mL bevacizumab (2.5 mg per 0.1 mL) (group 4). Digital photographs of the eyes were obtained and the surface areas of corneal neovascularization were measured on days 7 and 14 after subconjunctival injections. On days 7 and 14, 3 rabbits were randomly chosen and the eyes were extracted. Half of the corneal specimens were analyzed histopathologically, and the other half were used to measure the concentrations of vascular endothelial growth factor (VEGF) and IL-6 using a multiplex bead assay, and the levels were compared with those of the controls. Results: The surface areas of induced corneal neovascularization were significantly smaller in groups 3 and 4 (2.5 mg of tocilizumab and 2.5 mg of bevacizumab) compared with the control group on days 7 and 14 (P < 0.05). Group 2 did not show significant difference from the control group on days 7 and 14. There were no differences observed in the reduced neovascularization areas in groups 3 and 4 on days 7 and 14. The concentrations of VEGF in groups 3 and 4 were significantly lower than in the control group, and IL-6 mRNA levels were significantly lower in group 3 than in the other groups (P < 0.001) on days 7 and 14. Immunohistochemical analysis confirmed the reduced expression of VEGF in all 3 experimental groups compared with the control group. Conclusions: An antiangiogenic effect was observed after subconjunctival injection of 2.5 mg tocilizumab to an extent similar to that seen with 2.5 mg bevacizumab, which indicates that subconjunctival application of tocilizumab is effective for the inhibition of corneal neovascularization.
引用
收藏
页码:1088 / 1094
页数:7
相关论文
共 50 条
  • [1] Effects of topical and subconjunctival use of bevacizumab on corneal neovascularization in rabbits' eyes
    Aparecido Lopes, Gerson Jorge
    Barbante Casella, Antonio Marcelo
    Oguido, Ana Paula
    Matsuo, Tiemi
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2017, 80 (04) : 252 - 256
  • [2] Subconjunctival bevacizumab for corneal neovascularization
    Mesut Erdurmus
    Yuksel Totan
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245 : 1577 - 1579
  • [3] Subconjunctival bevacizumab for corneal neovascularization
    Doctor, Priyanka P.
    Bhat, Pooja V.
    Foster, C. Stephen
    CORNEA, 2008, 27 (09) : 992 - 995
  • [4] Subconjunctival bevacizumab for corneal neovascularization
    Erdurmus, Mesut
    Totan, Yuksel
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (10) : 1577 - 1579
  • [5] Subconjunctival bevacizumab for corneal neovascularization
    Gueudry, J.
    Richez, F.
    Tougeron-Brousseau, B.
    Genevois, O.
    Muraine, M.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2010, 33 (09): : 630 - 636
  • [6] Subconjunctival bevacizumab for corneal neovascularization
    Zaki, Ahmed A.
    Farid, Samar F.
    ACTA OPHTHALMOLOGICA, 2010, 88 (08) : 868 - 871
  • [7] The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization
    Eski, M. T.
    Teberik, Kuddusi
    Oltulu, Pembe
    Ankarali, Handan
    Kaya, Murat
    Alpay, Merve
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [8] The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization
    Eski, M. T.
    Teberik, Kuddusi
    Oltulu, Pembe
    Ankarali, Handan
    Kaya, Murat
    Alpay, Merve
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [9] Subconjunctival bevacizumab lnjection for corneal neovascularization
    Bahar, Irit
    Kaiserman, Igor
    McAllum, Penny
    Rootman, David
    Slomovic, Allan
    CORNEA, 2008, 27 (02) : 142 - 147
  • [10] Subconjunctival bevacizumab, a potential therapeutic strategy for treatment of corneal neovascularization
    Hashem, Hisham A.
    Zaki, Iman M. A.
    Ramzy, Mohamed
    LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION, 2010, 7 (03): : 112 - 116